Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (743)	3/1/2000 10:27:00 PM
From: jeffbas	Respond to of 52153

Peter, on the potential GZMO news front let me add some things: - the quarterly report, shortly - I expect that over the next 90 days we will hear something on the financing front, if nothing more than exercising their $30 million equity financing option with Genzyme. However, it would actually be dumb to do that as opposed to public or private financing, keeping that line in reserve for a rainy day. - There is a May scientific conference where I hope they will report (favorable) results of the melanoma vaccine trials. - Possible coverage. On the valuation front, I think that even in frenzy land these stocks will still tend to have somewhat reasonable relationships to each other, as the most overpriced ones get sold to buy the less overpriced ones. Can YOU identify any peers whose valuations GZMO might be heading toward?